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Abstract 
Background: The efficacy of treating acute myocardial ischemic damages depends, to a large extent, on the devel-
opment of technologies for predicting their course and outcome. The aim of this paper was to explore whether it 
would be possible to consider the content of free circulating mitochondrial DNA as a danger-associated molecular 
pattern for assessing the probability of death from myocardial infarction.
Methods: We have analyzed the clinical outcomes based on discharge summaries and autopsy reports obtained in 
the course of the PROTOCOL observational trial. This study was approved by the Irkutsk Scientific Center of Surgery 
and Traumatology ethics committee (protocol No. 3, 10.08.2015). To examine whether the assessment of the level of 
free circulating mtDNA in acute coronary syndrome can help predicting clinical outcomes, all patients were divided 
into two groups: group 1, involving those who survived during 30 days after hospitalization, and group 2, involving 
those who died during this time. A quantitative analysis of the free circulating mtDNA was conducted using the PCR 
method in situ.
Results: The analysis showed that in patients who survived the level of freely circulating mtDNA (36.0 copies/ml) was 
164 times lower than in those who died (5900 copies/ml, p = 0.049). It should be mentioned that according to the 
logistic regression analysis, the probability of death of patients with the increased level of blood plasma mtDNA (more 
than 4000 copies/ml) is 50%.
Conclusions: Thus, the PROTOCOL observational trial proved that the increase in the content of free circulating 
mtDNA in blood is a predictor of lethal outcome in patients with acute coronary syndrome.
Trial registration The observational studies (those in which the assignment of the medical intervention is not at the 
discretion of the investigator) do not require registration.
Keywords: Acute coronary syndrome, Myocardial ischemia, Mitochondrial DNA, Danger-associated molecular 
patterns
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Background
The development of technologies for predicting acute 
myocardial ischemic damages helps to increase the effi-
cacy of treatment to a great extent. Currently, the so-
called danger-associated molecular patterns (DAMPs) 
are considered to be predictors of adverse clinical out-
comes and deaths from various diseases. DAMPs include 
nuclear and cytoplasmic macromolecules activating the 
components of the innate immune system after having 
been released from injured tissues [1]. One of the little-
studied but promising DAMPs reflecting intense cyto-
lytic processes is free circulating mitochondrial DNA 
(mtDNA). Today, the level of blood mtDNA is used to 
forecast complications and morbidity for malignant neo-
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of death in emergency patients [2–4]. However, the 
dynamics of concentration of free circulating blood 
mtDNA in acute myocardial ischemic damages has not 
been explored yet. Therefore, it seems vital to examine 
the possibility of using this parameter as a biomarker of 
damaged cardiac muscle cells in comprehensive diagno-
sis of myocardial infarction. It was already explored the 
dynamics of the level of free circulating blood plasma 
mtDNA in acute myocardial ischemia and observed the 
increase in blood plasma mtDNA concentration [5–7]. 
Recently, we found the raise of concentration of free cir-
culating mitochondrial DNA in blood after injection of 
adrenaline that caused the development of multiple small 
focal myocardial ischemia in Wistar rats [8, 9]. Recent 
observations [10] reveal the molecular mechanism 
behind the development of acute heart failure in animal 
models, where mitochondrial DNA is an important path-
ogenic factor. At high level of mtDNA in blood, it can 
cause inflammation and disorder of heart function [10]. 
The aim of this paper was to explore whether it would be 
possible to consider the content of free circulating mito-
chondrial DNA as a danger-associated molecular pattern 




We included, in the study, the results of medical exami-
nation (non-interventional trial) of the patients who 
signed informed consents for processing their data in 
the course of the Personalized the Rapy with clOpidogrel 
during coronary sTent implantation for acute coronary 
syndrOme taking into aCcount genetic pOLymorphism 
(PROTOCOL) prospective multicenter observational 
study. (Organization conducting the study: Institute of 
Chemical Biology and Fundamental Medicine, SB RAS; 
Collaborators: Department of Medicobiological Stud-
ies and Technologies, Irkutsk Scientific Center, SB RAS, 
and Irkutsk Scientific Center of Surgery and Traumatol-
ogy; Protocol Authors: Prof. K. A. Apartsin, Prof. G. I. 
Lifshitz, and N. Yu. Knauer; Study Director: Prof. G. I. 
Lifshitz, Doctor of Medicine, Head of the Laboratory of 
Personalized Medicine, Institute of Chemical Biology and 
Fundamental Medicine, SB RAS) [11]. This non-interven-
tional trial was approved by the Irkutsk Scientific Center 
of Surgery and Traumatology ethics committee (protocol 
No. 3, 10.08.2015).
Emergency patients were admitted to the Irkutsk State 
Regional Hospital for percutaneous coronary intervention 
(PCI) by coronary stenting implantation (CSI) on account 
of in acute coronary syndrome (ACS). They were adminis-
tered with load clopidogrel dose about 2 h before PCI, and 
afterwards, with daily maintenance dose of clopidogrel 
during 30  days after CSI. Three medical examinations 
(standard CSI trials) were conducted (48 ± 6 h after CSI; 
at the day of discharge from the hospital; and 30 ± 3 days 
after CSI) to assess the efficacy and safety endpoints [12]. 
According to the criteria of Academic Research Consor-
tium, definite or probable stent thrombosis was registered 
as efficacy endpoint [13]. Heavy and medium clinically 
significant bleeding was regarded as safety endpoint. At 
stages 1‒3, the data were collected during medical exami-
nations; at stage 4, as telephone survey.
Criteria for being included in the research
1. ACS diagnosis requiring urgent hospitalization and 
CSI;
2. Patient’s informed consent to participate in the 
observational study.
Criteria for non‑inclusion
1. Recent administration of clopidogrel and/or antico-
agulants (during the last 14 days);
2. Thrombolytic therapy at the pre-hospital stage;
3. Active (clinically significant) bleeding at the time of 
screening during the first examination (stage 1);
4. Clopidogrel intolerance in past medical history;
5. PCI without CSI (e.g., diagnostic procedure or bal-
loon angioplasty);
6. Refusal of the patient (or of his legal representative in 
case if the patient cannot express his will) to partici-
pate in the study at any stage;
7. Incapability of the patient, according to the 
researcher, to interact (participate in the survey) dur-
ing stage 4 held as telephone survey.
Clinical outcomes were analyzed based on discharge 
summaries and autopsy reports. In accordance with clini-
cal judgment, two outcomes were distinguished: favora-
ble progression after CSI (alleviation of pain syndrome, 
general recovery, and absence of signs of stent thrombo-
sis), and unfavorable progression (death after CSI from 
heart failure, clinical symptoms of stent thrombosis, and 
progressive functional disorders). Blinding assessment 
of the course after CSI was conducted by an experienced 
cardiologist based on the data provided. We analyzed 14 
enumerated test tubes and selected blood plasma sam-
ples of patients with favorable and unfavorable progres-
sions after CSI. Appraisal sheets with clinical laboratory 
data of the patients and integral assessment (favorable or 
unfavorable progression after CSI) marked in accordance 
with the numbers on test tubes were sent for unblinding 
procedure conducted by an analyst evaluating the level of 
mitochondrial DNA. The unblinding procedure was car-
ried out after the analysis of the level of freely circulating 
mitochondrial DNA had been done.
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Analysis of the level of free circulating blood mtDNA
At stage 1, blood samples used for evaluating the concen-
tration of mitochondrial DNA were collected not later 
than after 2 h upon the administration of the load clopi-
dogrel dose; at stage 2, not later than after 48 ± 6 h after 
CSI. To analyze mitochondrial DNA, we collected plate-
let-poor plasma obtained by centrifugation of patient’s 
blood at 3000 rpm during 15 min. Isolation of total DNA 
from blood plasma was performed with PROBA-NK 
reagent kit (DNA-Technology, Russia) according to the 
manufacturer’s instruction. The quantitative analysis of 
mtDNA was conducted using PCR method in  situ with 
the reaction mixture containing SYBR Green (MaximaTM 
SYBR Green/ROX qPCR Master Mix–Thermo Fisher 
Scientific Inc., USA). The amplification of 16S rRNA gene 
fragment (length 230 base pairs) was performed (forward 
primer: 5′-CAGCCGCTATTAAAGGTTCG-3′; reverse 
primer: 5′-GGGCTCTGCCATCTTAACAA-3′) [2]. To 
draw a calibration straight line (Fig. 1), a set of samples 
with the precisely known concentration (10, 1000, and 
1,000,000  copies/ml) of the above stated gene (length 
490 base pairs) containing the analyzed sequence with 
the length of 230 base pairs was used (forward primer: 
5′-GGGATAACAGCGCAATCCTA-3′; reverse primer: 
5′-ACGTTGGGGCCTTTGCGTAG-3). Oligonucleotide 
synthesis was carried out by Syntol OOO (LLC) (Mos-
cow, Russia). The DT lite amplifier (DNA-Technology, 
Russia) was used to perform PCR in situ.
Experimental statistics
The results of the quantitative assessment were presented 
as a median (25–75  percentiles). We applied non-par-
ametric statistical methods and conducted exploratory 
data analysis using Spearman’s rank correlation coeffi-
cient. Based on this analysis, we built a logistic regression 
model of death probability depending on mtDNA level 
in blood plasma. To calculate the statistical significance 
of differences in mtDNA level in survivors and deceased 
patients, the Mann–Whitney test criterion was used.
Results and discussion
To examine whether the assessment of the level of free 
circulating mtDNA in acute coronary syndrome can help 
in predicting clinical outcomes, all unblinded patients 
were divided into two groups: group 1, involving those 
who survived during 30  days after hospitalization, and 
group 2, involving those who died due to ACS during 
this time. Therefore, equivalence in the ratio of deceased 
and survived patients is defined by the number of retro-
spectively included examination results and patients’ CSI, 
who signed informed consent for data handling within 
the Prospective Multicenter Observational Investiga-
tion PROTOCOL. Enlarging the group of deceased at the 
expense of patients not included into the PROTOCOL 
study would violate the standards of the present investi-
gation. On the basis of the presented data, the blinding 
expert evaluation of the clinical course after CSI was con-
ducted. Characteristics of the patients (sex, age, intercur-
rent diseases, and the level of blood plasma mtDNA) are 
presented in Table 1. In general, the ratio of survived and 
deceased patients roughly corresponds to the data of pre-
viously performed CSI trials [12]. Diabetes mellitus was 
observed in 60 and 67% of patients from groups 1 and 
2, respectively. Essential hypertension was registered in 
group 1 (54.5% of patients) and group 2 (100%). An unfa-
vorable course of acute coronary syndrome was observed 
in the patients of group 1 (30%) and group 2 (100%). 
The analysis showed the level of freely circulating blood 
mtDNA in those who survived was 164 times lower than 
in those who died (p = 0.049). The connection between 
the level of mtDNA and lethal outcome evaluated using 
the Spearman’s rank correlation coefficient (R2) is 0.4 
(p = 0.01). At the same time, the logistic regression anal-
ysis of death probability in patients with acute coronary 
syndrome depending on concentration of mitochondrial 
blood plasma DNA upon arrival at the hospital indi-
cates that the death probability of patients with increased 
mtDNA level (more than 4000 copies/ml) is 50% (Fig. 2). 
This conclusion is in agreement with the work by Naka-
hira [3] where the authors prove the possibility of regard-
ing the level of free circulating mtDNA as predictor of 
death in emergency patients.
Recently [14], it was shown that plasma levels of 
mtDNA in elderly healthy are much higher than in young 
people. The authors measured mtDNA content in plasma 
from young (average age 36.8) and old (average age 82.7) 
trauma patients and corresponding young (average age 
25) and old (average age 72) volunteers. Using young vol-
unteers’ mtDNA levels as a control value of 100%, elderly 
volunteers, young trauma patients, and elderly trauma Fig. 1 Calibration straight line. Ct threshold cycle
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patients had values of 385, 364, and 2156, respectively 
[14].
The following observation made by us in the course 
of this study is worth mentioning and requires future 
investigation: only women turned out to be in the group 
of deceased patients after unblinding of mtDNA analy-
sis results. At this stage of investigations, such a result 
could be possibly explained by the number of patients 
included into the PROTOCOL investigation. However, 
at present, we cannot fully exclude the existence of 
genetically determined association of patients’ gender 
with the blood plasma mtDNA content. Unfortunately, 
by now, we could not find any available published data 
on gender differences in the content of freely circulating 
blood mtDNA, though there exist data concerning the 
higher level of whole blood mtDNA of elderly women 
in comparison with men [15]. The discovered mtDNA 
level was determined by the number of platelets and 
white blood cells [16]. Taking this into consideration, 
we cannot use these data for discussion of the results in 
this study.
It is evident that to gain a deeper understanding of the 
reasons for such a drastic increase in the mtDNA content 
in patients with ACS, we need the data that are currently 
lacking as to the state and dynamics of changes in the 
structural and functional organization of mitochondrial 
membrane and cardiomyocyte cell membranes. Consid-
ering current knowledge of the biological nature of circu-
lating nucleic acids [17], one can assume that the increase 
in mtDNA concentration above normal is caused by two 
consequent events: (i) release of mtDNA from mito-
chondria into cytoplasm, and (ii) release of mtDNA 
from cytoplasm of cells tissues and organs subjected to 
abnormally high stresses. The release of mtDNA from 
mitochondria into cytoplasmic space may occur both as 
a result of disruption of the continuity of mitochondrial 
membrane and of induction of mitochondrial perme-
ability transition pore (MPTP) opening and/or potential 
reversibility of the earlier discovered mechanism of active 
DNA uptake by mitochondria [18, 19]. As for appearance 
of mtDNA in extracellular space, the possible mechanism 
here could be the release of mtDNA from the myocar-
dial infiltrating cardiomyocytes and phagocytes dying by 
necrosis-like programmed cell death. Another possible 
way could be the release of mtDNA from cells with small 
membrane vesicles budding off from their surface [20]. 
Another mechanism of increasing the level of free blood 
mtDNA is their active release from cells caused by stress 
stimulus [21]. This process is mostly explored with regard 
to leukocytes releasing mtDNA included into the so-
called extracellular traps [22]. Considering rapid changes 
of the mtDNA level, one cannot exclude the possibility 
that the drastic increase in the content of blood mtDNA 
in patients with ACS may be caused by the programmed 
mtDNA release from mitochondria and cells and, in turn, 
may serve as an additional regulatory factor for inducing 
massive apoptosis leading to death.
It is certain that comprehensive understanding of the 
processes at the molecular, cellular, and organ levels 
increasing the level of blood mtDNA will allow to reveal 
new cell targets for personalized therapy of patients with 
Table 1 General characteristics of patients included in the clinical study
Survivors Deceased p
Number of patients 11 3 –
Age (years) 53.0 (52.0; 74) 87 (65.0; 87) 0.039
Sex (f ) 2 (20%) 3 (100%) 0.035
Diabetes mellitus 6 (60%) 2 (67%) 1.000
Essential hypertension 6 (54.5%) 3 (100%) 0.496
Unfavorable course of ACS according to experts 3 (30%) 3 (100%) 0.070
Content of mtDNA (copies/ml) 36.0 (30.0; 1800) 5900 (920.0; 6800) 0.049
Fig. 2 Logistic regression of death probability in patients with acute 
coronary syndrome depending on concentration of mitochondrial 
DNA upon arrival at the hospital
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acute coronary syndrome. These data are important for 
purposes of translational medicine aimed at rapid intro-
duction of the findings of fundamental studies to hospital 
practice [23].
Conclusions
As a whole, the data obtained in the course of the PRO-
TOCOL clinical study prove that increase in the content 
of freely circulating blood mtDNA up to a certain level is 
a clear predictor of lethal outcome in patients with ACS. 
This will help to forecast and influence the clinical course 
of myocardial infarction.
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